5AM VENTURE MANAGEMENT LLC
Q3 2025 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001799883
· CRD 160395
· SEC-registered investment adviser
$273.0M Reported Value Total
5AM VENTURES reports 14 total accounts under management (AUM). There are 14 discretionary accounts valued at $1,264,695,419, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $947.0M gross asset value
Venture Capital Fund: $625.3M · Private Equity Fund: $271.8M · Hedge Fund: $49.9M
Source: Form ADV filed 2026-03-30
Reported value
$273.0M
Quarter over quarter
+29.4%
Holdings
25
Top-10 concentration
69.9%
Key People
Form ADV owners & control persons
Kush M Parmar
MEMBER, 5AM VENTURE MANAGEMENT, LLC
Andrew James Schwab
MEMBER, 5AM VENTURE MANAGEMENT LLC
Lauren Alison Daniel
CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 14, 2025 |
| Form | 13F-HR |
| Reported value | $273.0M |
| Positions | 25 |
| Change in reported value | +5.0% |
| New positions | 1 |
| Exited positions | 5 |
| Position turnover | 20.0% |
| Top-10 concentration | 69.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
16 | $287.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $360.2M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
21 | $318.1M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
25 | $273.0M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $260.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $264.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $419.1M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
28 | $484.0M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
28 | $447.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
26 | $446.6M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
25 | $377.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $347.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
24 | $401.4M |
|
Q1 2023 13F
Filed May 15, 2023
|
24 | $391.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $372.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $522.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
21 | $404.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
19 | $457.8M |
|
Q4 2021 13F
Filed Feb 3, 2022
|
17 | $532.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
16 | $492.5M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SKYE SKYE BIOSCIENCE INC | $38.0M | 13.94% |
| 2 | TRDA ENTRADA THERAPEUTICS INC | $24.7M | 9.04% |
| 3 | PHVS PHARVARIS N V | $19.9M | 7.29% |
| 4 | CAMP CAMP4 THERAPEUTICS CORP | $17.6M | 6.45% |
| 5 | CNTA CENTESSA PHARMACEUTICALS PLC | $16.5M | 6.05% |
| 6 | VRDN VIRIDIAN THERAPEUTICS INC | $15.9M | 5.82% |
| 7 | ELVN ENLIVEN THERAPEUTICS INC | $15.8M | 5.79% |
| 8 | EYPT EYEPOINT PHARMACEUTICALS INC | $15.0M | 5.48% |
| 9 | DNTH DIANTHUS THERAPEUTICS INC | $14.4M | 5.26% |
| 10 | TYRA TYRA BIOSCIENCES INC | $13.1M | 4.81% |
| 11 | CLDX CELLDEX THERAPEUTICS INC NEW | $12.9M | 4.71% |
| 12 | ERAS ERASCA INC | $11.8M | 4.32% |
| 13 | PRAX PRAXIS PRECISION MEDICINES I | $9.0M | 3.3% |
| 14 | GHRS GH RESEARCH PLC | $8.2M | 3.0% |
| 15 | TECX TECTONIC THERAPEUTIC INC | $8.0M | 2.94% |
| 16 | BHVN BIOHAVEN LTD | $7.2M | 2.63% |
| 17 | ARTV ARTIVA BIOTHERAPEUTICS INC | $6.8M | 2.47% |
| 18 | SRZN SURROZEN INC | $4.0M | 1.46% |
| 19 | TARA PROTARA THERAPEUTICS INC | $3.5M | 1.27% |
| 20 | ALEC ALECTOR INC | $2.9M | 1.08% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.